Active Motif, a provider of epigenetics and multiomics solutions, announces an exclusive global distribution agreement with Arima Genomics for advanced 3D genomics solutions. The companies say the arrangement expands Active Motif’s research genomics portfolio, while supporting Arima’s strategic focus on its clinical diagnostics platform. The announcement is dated July 6, 2026, and is issued from Carlsbad, California. Under the terms described in the release, Arima’s products are distributed globally through Active Motif under exclusivity, positioning Active Motif to add 3D genomics capabilities to its existing offerings for mechanistic and translational research. The agreement is framed as a business expansion for Active Motif and as a pathway to align Arima’s commercial reach with its clinical diagnostics strategy. The sources provided do not specify financial terms, contract duration, product list details, or implementation timelines beyond the agreement’s start as presented in the announcement.